These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 11034276)

  • 1. Treatment options for extended-spectrum beta-lactamase-producers.
    Essack SY
    FEMS Microbiol Lett; 2000 Sep; 190(2):181-4. PubMed ID: 11034276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and antibacterial resistance patterns of extended-spectrum beta-lactamase producing Gram-negative bacteria isolated from ocular infections.
    Rameshkumar G; Ramakrishnan R; Shivkumar C; Meenakshi R; Anitha V; Venugopal Reddy YC; Maneksha V
    Indian J Ophthalmol; 2016 Apr; 64(4):303-11. PubMed ID: 27221683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-lactamase-mediated resistance: a biochemical, epidemiological and genetic overview.
    Gutkind GO; Di Conza J; Power P; Radice M
    Curr Pharm Des; 2013; 19(2):164-208. PubMed ID: 22894615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on prevalence and molecular mechanisms of antibacterial resistance in Gram-negative pathogens of nosocomial infections in hospitals of Moscow and Perm'].
    Mudrak DE; Ikriannikova LN; Sidorenko SV; Il'ina EN
    Antibiot Khimioter; 2007; 52(7-8):10-6. PubMed ID: 18986019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG; Johnson JK; Bork JT; Heil EL
    Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulbactam-containing beta-lactamase inhibitor combinations.
    Akova M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():185-8. PubMed ID: 18154545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
    Rotschafer JC; Ostergaard BE
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Lactamases of increasing clinical importance.
    Bush K
    Curr Pharm Des; 1999 Nov; 5(11):839-45. PubMed ID: 10539991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-spectrum beta-lactamase-mediated resistance among bacterial isolates recovered from ocular infections.
    Jayahar Bharathi M; Ramakrishnan R; Ramesh S; Murugan N
    Ophthalmic Res; 2012; 47(1):52-6. PubMed ID: 21720185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHV-type beta-lactamases.
    Tzouvelekis LS; Bonomo RA
    Curr Pharm Des; 1999 Nov; 5(11):847-64. PubMed ID: 10539992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of a broad-spectrum cephalosporin (Ro 48-8391) alone and in combination with two novel beta-lactamase inhibitors (Ro 48-5545 and Ro 48-8724).
    Jones RN; Marshall SA; Varnam DJ
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):85-94. PubMed ID: 9823530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-spectrum beta-lactamases.
    Patterson JE
    Semin Respir Infect; 2000 Dec; 15(4):299-307. PubMed ID: 11220412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
    Shah AA; Hasan F; Ahmed S; Hameed A
    Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissemination of IncF plasmids carrying beta-lactamase genes in Gram-negative bacteria from Nigerian hospitals.
    Ogbolu DO; Daini OA; Ogunledun A; Terry Alli OA; Webber MA
    J Infect Dev Ctries; 2013 May; 7(5):382-90. PubMed ID: 23669427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of characterized β-lactamase-producing Gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations.
    Yoshizumi A; Ishii Y; Aoki K; Testa R; Nichols WW; Tateda K
    J Infect Chemother; 2015 Feb; 21(2):148-51. PubMed ID: 25444674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.